Study drug CB-103 for advanced adenoid cystic cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenoid cystic carcinoma confirmed by pathology, and it is advanced, metastatic, or has come back and can’t be cured
- Your tumor test shows an activating NOTCH pathway mutation (a genetic change that turns the pathway on)
- You must be 18 or older, and well enough to do daily activities (ECOG 0–1)
- You can swallow study pills, and you have at least one measurable spot tumor seen on scans
- Your blood counts and organ lab tests are within required ranges (including white blood cells, hemoglobin, platelets, kidney, liver, and bilirubin)
- You can safely take the assigned oral medication plan (lenvatinib or abemaciclib), including insurance approval or support for lenvatinib if you’re in that group
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
This trial tests two medications given before surgery for advanced adenoid cystic carcinoma in the nose or sinuses. The goal is to shrink the tumor and make surgery safer and more effective.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
Hear when a new Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.